Menu

Scientist Who Received Millions From NIH Leaves Alabama Posts

An investigation finds 20 papers by Santosh Katiyar, who studied alternative treatments for cancer, include image manipulation.

May 24, 2018
Ivan Oransky, Retraction Watch

Santosh KatiyarVA RESEARCH CURRENTSA professor who received about $5 million in grants from the National Institutes of Health left his posts at the University of Alabama, Birmingham (UAB), and Birmingham VA Medical Center last year after an investigation found evidence of image manipulation in 20 of his papers, Retraction Watch has learned.

Since March 30, five articles by Santosh Katiyar that explore alternative approaches to treating skin cancer in animal models have been retracted as a result of the institutions’ probe.

The university and medical center requested a total of 20 papers be retracted, according to UAB research integrity officer Pam Bounelis. “Certain published images within those papers were not substantiated by available data, or the scientific conclusions of the publication were not supported,” Bounelis tells Retraction Watch. “Dr. Katiyar’s employment at UAB was ended on May 1, 2017.”

In an email, Bounelis says a journal alerted UAB to concerns about Katiyar's work in 2012 and the university began looking into the allegations then. UAB declined to share a copy of the report of the investigation.

Four of the recently retracted papers were published by Carcinogenesis, joining another retraction of Katiyar’s work in that journal for “an error in presentation of data” from 2012. The fifth was published in Photochemistry and Photobiology. Together, the five recently removed papers were cited just shy of 500 times, according to Clarivate Analytics’s Web of Science.

Jean Cadet, editor of Photochemistry and Photobiology, tells Retraction Watch that Katiyar’s former institutions contacted the journal in August 2017 with the conclusions of their investigations.

Vijayalakshmi Nandakumar, who is a coauthor of one of the Carcinogenesis papers and now a postdoc at the ‎Mayo Clinic in Rochester, Minnesota, says he “fully support[s] the retraction.”

Katiyar’s current whereabouts are unknown. In a 2006 profile in VA Research Currents about his work on green tea and skin cancer, Katiyar linked his choice of research subjects to personal experience. “I lost my mother to breast cancer,” he said. “I had done my PhD in nutrition, and I realized that my parents had devoted a lot of time and energy to my education. Yet, I could not help my mother. So I resolved to do something to help all the other mothers who are still here. I decided I would work on cancer—how it can be prevented, particularly by dietary supplements and nutrients.”

Reporting contributed by Victoria Stern

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing